2. Academic Validation
  3. ITGA2 Mediates the Resistance of Hepatocellular Carcinoma to Lenvatinib by Activating the AKT/FOXO3A Signaling Pathway

ITGA2 Mediates the Resistance of Hepatocellular Carcinoma to Lenvatinib by Activating the AKT/FOXO3A Signaling Pathway

  • Cancers (Basel). 2025 Aug 29;17(17):2846. doi: 10.3390/cancers17172846.
Kai Gong 1 2 3,  Bin Xu 1 2 3,  Lian Gong 4,  Ming Zhong 5,  Chun Han 1 2 3,  Yuechuan Liu 1 2 3,  Zeli Yin 1 2 3,  Xiangnan Liang 1 2 3,  Qiuxiang Wang 1 2 3,  Genhua Ye 1 2 3,  Binwen Sun 1 2 3,  Liming Wang 1 2 3
Affiliations

Affiliations

  • 1 Engineering Research Center for New Materials and Precision Treatment Technology of Malignant Tumors Therapy, The Second Affiliated Hospital, Dalian Medical University, Dalian 116023, China.
  • 2 Engineering Technology Research Center for Translational Medicine, The Second Affiliated Hospital, Dalian Medical University, Dalian 116023, China.
  • 3 Division of Hepatobiliary and Pancreatic Surgery, Department of General Surgery, The Second Affiliated Hospital of Dalian Medical University, 467 Zhongshan Road, Dalian 116023, China.
  • 4 Department of Radiotherapy, The Seventh Afffliated Hospital of Sun Yat-Sen University, Shenzhen 518107, China.
  • 5 Department of General Surgery, The Seventh Afffliated Hospital of Sun Yat-Sen University, Shenzhen 518107, China.
PMID: 40940943 DOI: 10.3390/cancers17172846
Abstract

The global incidence of primary liver Cancer ranks sixth among malignant tumors, while its mortality rate ranks third and is the second leading cause of cancer-related deaths in China [...].

Keywords

E7820; drug resistance; hepatocellular carcinoma; integrin; lenvatinib.

Figures
Products
Inhibitors & Agonists
Other Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z